Dearfield Kerry L, Moore Martha M
Office of the Science Advisor (8105R), US Environmental Protection Agency, Washington, District of Columbia, USA.
Environ Mol Mutagen. 2005 Dec;46(4):236-45. doi: 10.1002/em.20176.
Genetic toxicology data are used worldwide in regulatory decision-making. On the 25th anniversary of Environmental and Molecular Mutagenesis, we think it is important to provide a brief overview of the currently available genetic toxicity tests and to outline a framework for conducting weight-of-the-evidence (WOE) evaluations that optimize the utility of genetic toxicology information for risk assessment. There are two major types of regulatory decisions made by agencies such as the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA): (1) the approval and registration of pesticides, pharmaceuticals, medical devices, and medical-use products, and (2) the setting of standards for acceptable exposure levels in air, water, and food. Genetic toxicology data are utilized for both of these regulatory decisions. The current default assumption for regulatory decisions is that chemicals that are shown to be genotoxic in standard tests are, in fact, capable of causing mutations in humans (in somatic and/or germ cells) and that they contribute to adverse health outcomes via a "genotoxic/mutagenic" mode of action (MOA). The new EPA Guidelines for Carcinogen Risk Assessment [Guidelines for Carcinogen Risk Assessment, USEPA, 2005, EPA Publication No. EPA/630/P-03/001F] emphasize the use of MOA information in risk assessment and provide a framework to help identify a possible mutagenic and/or nonmutagenic MOA for potential adverse effects. An analysis of the available genetic toxicity data is now, more than ever, a key component to consider in the derivation of an MOA for characterizing observed adverse health outcomes such as cancer. We provide our perspective and a two-step strategy for evaluating genotoxicity data for optimal use in regulatory decision-making. The strategy includes integration of all available information and provides, first, for a WOE analysis as to whether a chemical is a mutagen, and second, whether an adverse health outcome is mediated via a mutagenic MOA.
遗传毒理学数据在全球范围内被用于监管决策。在《环境与分子诱变》创刊25周年之际,我们认为简要概述当前可用的遗传毒性测试,并概述一个进行证据权重(WOE)评估的框架非常重要,该框架可优化遗传毒理学信息在风险评估中的效用。环境保护局(EPA)和食品药品监督管理局(FDA)等机构做出的监管决策主要有两种类型:(1)农药、药品、医疗器械和医疗用品的批准与注册,以及(2)空气、水和食品中可接受暴露水平标准的设定。遗传毒理学数据被用于这两类监管决策。目前监管决策的默认假设是,在标准测试中显示具有遗传毒性的化学物质实际上能够在人类(体细胞和/或生殖细胞)中引起突变,并且它们通过“遗传毒性/诱变”作用模式(MOA)导致不良健康后果。新的EPA致癌物风险评估指南[《致癌物风险评估指南》,美国环境保护局,2005年,EPA出版物编号EPA/630/P-03/001F]强调在风险评估中使用作用模式信息,并提供了一个框架,以帮助确定潜在不良反应的可能诱变和/或非诱变作用模式。现在,对可用遗传毒性数据的分析比以往任何时候都更是推导用于表征观察到的不良健康后果(如癌症)的作用模式时需要考虑的关键组成部分。我们提供了我们的观点以及一个两步策略,用于评估遗传毒性数据以便在监管决策中得到最佳利用。该策略包括整合所有可用信息,首先,对一种化学物质是否为诱变剂进行证据权重分析,其次,分析不良健康后果是否通过诱变作用模式介导。